Research database
The following are current research studies and trials being conducted by members of DC Rheum in the Greater DC Metropolitan area.
If you have posted research that is no longer active, please delete the entry
Research is by grouped disease. Select a from below to jump to that area.
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Rheumatoid Arthritis Using H.P. Acthar® Gel |
Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action |
Michelle Grimm |
| Mallinckrodt Pharmaceuticals |
888-717-8839/888-71- |
|
| Frederick, MD |
mgrimm@arthritistreatmentcenter.com |
| Submitted: April 1, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Tofacitinib vs Adalimumab in Subjects with Cardiovascular Risk Factors |
Subjects greater than 50 yrs in age, currently on MTX with cardiovascular risk factors who have not been exposed to Xeljanz or/and have not failed Humira. |
Megan Bishop, BS CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mbishop@arapc.com |
| Submitted: January 14, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Withdrawing Etanercept or MTX in subjects with Remission |
Must be on Enbrel and MTX. 24 week open label with 48 week extension for subjects who are in remission with RA. If disease worsens, subject’s will go back on their original treatment. |
Ashling Smith |
| The Center For Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
asmith@arapc.com |
| Submitted: January 18, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA) Trial |
Placebo controlled trial of stopping anti-TNF agents in patients with RA with low disease activity/remission (DAS28<2.6). |
Florina Constantinescu, PI |
| ACR/REF, MedStar Health Research Institute, NIAMS |
202-877-6274 |
|
| Multi-centered (PA, MD, DC, VA) |
florina.constantinescu@medstar.net |
| Submitted: February 21, 2018 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Diet and Arthritis |
The Physicians Committee for Responsible Medicine is conducting a study of plant based diet and its effects on Rheumatoid Arthritis. Non plant based foods have been implicated as pro inflammatory. |
- |
| The Physicians Committee for Responsible Medicine |
855-STUDY-18 |
|
| 5100 Wisconsin Ave NW, Suite 400, Washington, D.C. |
pcrm@pcrm.org |
| Submitted: March 12, 2018 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| 24wk, phase IV study using triple therapy treatments for RA. |
A study using triple therapy treatments against RA and effect on FDG PE-CT |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: April 26, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Otilimab vs Placebo vs Tofacitinib for Rheumatoid Arthritis |
A 52-week, phase 3 study comparing GM-CSF with placebo and with tofacitinib in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to conventional synthetic DMARDs or biologic DMARDs. |
Ashling Bauer, BA |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Otilimab vs Sarilumab vs Placebo for Rheumatoid Arthritis |
A 24-week, phase 3, comparing otilimab with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors. |
Ashling Bauer, BA |
| The Center for Rheumatology and Bone Research |
3019426610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Otilimab vs Placebo vs Tofacitinib for Rheumatoid Arthritis |
A 52-week, phase 3, comparing otilimab with placebo and with tofacitinib, in combination with methotrexate in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate. |
Ashling Bauer, BA |
| The Center for Rheumatology and Bone Research |
13019426610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| anti-CD40L vs Placebo for Rheumatoid Arthritis |
A Phase 2, Comparing an anti-CD40L vs Placebo In Patients With Rheumatoid Arthritis (Ra) |
Ashling Bauer, BA |
| The Center for Rheumatology and Bone Research |
13019426610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study with an Open |
A double blind placebo controlled phase 1b trial examining the safety of Omalizumab (anti-IgE antibody) in patients with mild to moderate lupus activity. |
Elizabeth Joyal, MSN |
| NIH/NIAMS |
301-435-4489 |
|
| NIH Clinical Center, Bethesda, Md |
ejoyal@nih.gov |
| Submitted: May 29, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Studies of the Pathogenesis and the Natural History of Systemic Lupus Eryth |
Natural History Study open to any individual 10 years old or older who meets the ACR's criteria for lupus. |
Elizabeth Joyal, MSN |
| NIH/NIAMS |
301-435-4489 |
|
| Clinical Center, Bethesda, MD |
ejoyal@nih.gov |
| Submitted: May 29, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| The Role of PPAR-gamma Agonists in imunodulation and Vascular Prevention in |
Assess the effects of pioglitazone, a PPAR agonist in SLE on vascular function and inflammation and on SLE disease activity. |
Yenealem Temesgen-Oyelakin, BSN |
| NIH/NIAMS |
301-451-4990 |
|
| Clinical Center, Bethesda, MD |
yenealem.temesgen-oyelakin@nih.gov |
| Submitted: May 29, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Fatigability and Cardiorespiratory Fitness in Adolescents and Young Women w |
Exercise study with emphasis on increasing cardiorespiratory fitness, reducing fatigue, and improving body image in adolescent girls and young women ages 13-25. |
Liana C. Wooten, DPT |
| George Mason University |
703-772-4510 |
|
| Fairfax VA |
lwooten@masonlive.edu |
| Submitted: February 23, 2017 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Upadacitinib vs ABBV-105 vs Upadacitinib and ABBV-105 |
Phase 2, 48wk, 15visits. A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: November 18, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Scleroderma Lung Study II (SLS II) |
Double blind study comparing cyclophosphamide to mycophenylate mofetil in interstitial lung disease in scleroderma. Study complete and results will be presented at ATS in May 2015 |
Aida Manu |
| NIH |
202-444-6211 |
|
| Georgetown University, Virginia Steen, site PI |
steenv@georgetown.edu |
| Submitted: February 5, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| IVIG in Refractory Diffuse Scleroderma |
Controlled trial of severe scleroderma skin (<5 years duration) refractory to celcept or methotrexate. |
Maia Zulmatashvili |
| Georgetown University (CSL Behring) |
202-444-6210 |
|
| Georgetown University |
steenv@georgetown.edu |
| Submitted: February 5, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Asset Trial (Abatacept in diffuse scleroderma) |
Double blind, placebo controlled trial for EARLY diffuse scleroderma (can be mild, but less than 2 years of symptoms) |
Carolyn Fridley |
| Bristol Myers Squibb |
202-444-6211 |
|
| Georgetown University |
steenv@georgetown.edu |
| Submitted: February 5, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| RISE SSc (Riociquat in Scleroderma) |
Double blind placebo controlled using Riociquat (a vasodilatory with anti fibrotic features), in early diffuse scleroderma with less than 2 years of symptoms |
Maia Zulmatashvili |
| Bayer Health |
202-444-6210 |
|
| Georgetown University |
steenv@georgetown.edu |
| Submitted: February 5, 2015 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Febuxostat Vs Allopurinol in Subjects with Historyof Cardiovascular Disease |
Subjects greater than 50 yrs in age with history of cardiovascular disease. Subjects are able to washout of ULT. |
Sara Hauffe, RN BSN |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
shauffe@arapc.com |
| Submitted: January 14, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowe |
Subject > 120Kg will Pegloticase open label study with 8 wks additional dosing extension |
Megan Lormore BS, CCRC |
| The Center For Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: January 11, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Krystexxa and SEL-212 Comparator for Pts with Refractory Gout |
A Study to Compare the Efficacy of SEL-212 to Krystexxa in Gout Patients Refractory to Conventional Therapy |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: April 26, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| The Efficacy and Safety Study of Methotrexate to Increase Response Rates in |
Phase 4, 52wks, 36visits. Patients with chronic gout refractory to conventional therapy. |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: November 18, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Natural History of Behcet's Disease |
A natural history study of Behcet's disease in American patients. Patients undergo an extensive clinical evaluation by dermatology, gastroenterology, neurology, ophthalmology, and rheumatology. Serum, blood, RNA, DNA, and tissue samples are collected for research purposes. We are interested in all patients with a diagnosis of Behcet's disease. |
Cailin Sibley, MD; Elizabeth Joyal, RN |
| NIH / NIAMS |
301-827-4259 |
|
| Bethesda, MD |
sibleych@mail.nih.gov |
| Submitted: September 7, 2012 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| A Pilot Treatment Study of Anakinra in Behcet's Disease |
Patients with Behcet's disease and active oral or genital ulcers will be treated with three months of open label anakinra therapy followed by a six month randomized withdrawal. The time to recurrence of ulcers after randomization will be measured as well as an exploratory assessment of biomarkers of disease. |
Cailin Sibley, MD; Elizabeth Joyal, RN |
| NIH / NIAMS |
301-827-4259 |
|
| Bethesda, MD |
sibleych@mail.nih.gov |
| Submitted: September 7, 2012 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Natural History of Systemic Vasculitis |
We have recently started a translational research program in vasculitis at NIAMS, in affiliation with the Vasculitis Clinical Research Consortium (VCRC). This study is a natural history study of patients with systemic vasculitis. We are interested in all patients with known or suspected small, medium, or large vessel vasculitis. Patients will undergo an extensive clinical evaluation and consultation. DNA, RNA, serum, and tissue will be collected for biomarker discovery programs. Novel imaging protocols will be offered to patients with medium and large vessel vasculitis, including whole body PET-CT, PET-MR, and MRA. |
Peter Grayson, MD |
| NIH / NIAMS |
301-827-9187 |
|
| Bethesda, MD |
peter.grayson@nih.gov |
| Submitted: November 13, 2013 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| MYORISK |
Research study to determine if persons with myositis and the anti-synthetase syndrome (with frequent interstitial lung disease) have experienced different environmental exposures before disease onset compared to other polymyositis/dermatomyositis patients and to healthy individuals. All adult or juvenile polymyositis/dermatomyositis patients diagnosed within the last year are eligible for enrollment. |
Ms. Tasia Long |
| NIEHS |
301-451-6031 |
|
| Bethesda, MD |
longtm@mail.nih.gov |
| Submitted: September 7, 2012 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Dose ranging study using Secukinumab for pt with active AS |
Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)
|
Janice Whyte-Whitworth, Pharm BS |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
jwhytewhitworth@arapc.com |
| Submitted: April 26, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Phase III, Bimikizumab vs Placebo |
37 wk, 7 visits looking at the efficacy and safety of Bimekizumab in the treatment of patients with active psoriatic arthritis. |
Ashling Bauer, BA, CRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: November 18, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Risankizumab (IL-23) vs Placebo |
Phase III, 208 wks, 25 visits. Patients with psoriatic arthritis who have a history of inadequate response to or intolerance to at least one DMARD therapy. |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: November 18, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Risankizumab (IL-23) vs Placebo |
Phase III, 208wks, 25 visits. Patients with active psoriatic arthritis who have a history of inadequate response or intolerance to biologic therapy(ies). |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: November 18, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Bimekizumab vs Placebo for Psoriatic Arthritis |
A Multicenter, Phase 3, Evaluating The Efficacy And Safety Of Bimekizumab In The Treatment Of Subjects With Active Psoriatic Arthritis |
Ashling Bauer, BA |
| The Center for Rheumatology and Bone Research |
13019426610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Filgotinib vs Placebo for Psoriatic Arthritis |
A Phase 3 Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy. |
Janice Whyte Whitworth, PharmB |
| The Center for Rheumatology and Bone Research |
13019426610 |
|
| Wheaton, MD |
jwhitworth@arapc.com |
| Submitted: September 23, 2020 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Tanezumab Vs NSAIDS for OA of hip or knee |
56 week long study of Tanezumab vs. NSAIDs with Tylenol as rescue medication. Subjects must be on stable dose of NSAIDs (naproxen, celebrex or diclofenac) with K-L of greater or equal to 2 at screening. |
Ashling Smith |
| The Center For Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
asmith@arapc.com |
| Submitted: January 18, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Tanezumab vs Placebo vs Tramadol for Chronic Low Back Pain |
56 week long study looking at the efficacy and safety of Tanezumab in subjects with chronic low back pain. Tylenol used for rescue medication. |
Ashling Smith |
| The Center For Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
asmith@arapc.com |
| Submitted: January 18, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Phase 3, 56 Week Study of SM04690 vs Placebo for OA Knee. |
A Phase 3, 56 Week Study Which Administers A Single Injection of SM04690 vs Placebo Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects. |
Ashling Bauer |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
abauer@arapc.com |
| Submitted: June 19, 2019 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Mirogabalin (Next Gen Lyrica) Vs Lyrica Vs Placebo in Subjects with Fibromy |
Subjects with moderate to severe pain associated with FM. 21 wk study with 52 wk open label. Must be willing to washout of current analgesic management. May stay on SSRIs and Acetaminophen given for breakthrough pain. |
Ashling Smith, BA |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
asmith@arapc.com |
| Submitted: January 14, 2016 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Siblings discordant for systemic rheumatic disorders |
NIH is enrolling families in which an adult or child has one of the following: Rheumatoid Arthritis/Juvenile Rheumatoid Arthritis or Systemic Lupus Erythematosus or Systemic Sclerosis or Myositis within 4 years of diagnosis. The study consists of a blood draw, urine collection and completing surveys. Participants must have a sibling of the same gender within 4 years of age without these diseases. Compensation is provided. Call 1-800-411-1222 (TTY: 1-866-411-1010) Refer to study 03-E-0099. The National Institutes of Health is part of the Department of Health and Human Services. |
Dr. Irene Whitt |
| NIEHS |
301-451-6270 |
|
| Bethesda, MD |
irene.whitt@nih.gov |
| Submitted: September 7, 2012 |
|
|
|
| Trial/Study name, sponsor, location |
Description |
Contact info |
|
| Giant Cell Arteritis (GCA) - Upadacitinib vs Placebo |
Phase 3, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis. |
Megan Lormore, BS, CCRC |
| The Center for Rheumatology and Bone Research |
301-942-6610 |
|
| Wheaton, MD |
mlormore@arapc.com |
| Submitted: April 26, 2019 |
|
|
|
